Almirall In The Market For Bolt-On Acquisitions
As New Psoriasis Products Start Well In Europe
Executive Summary
Much of Almirall's attention this year will be on submitting the potential atopic dermatitis blockbuster lebrikizumab in Europe but the Spanish firm is also looking at bringing in some other late-stage products.